×
About 18,833 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  9,249 results

Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Freque...
https://doi.org/10.1097/PAS.0000000000001716
The American Journal of Surgical Pathology; Tsai JH, Liau JY et. al.

Apr 16th, 2021 - The molecular characteristics of lymphoepithelioma-like intrahepatic cholangiocarcinoma (LELCC) remain elusive. We examined 27 LELCC cases through next-generation sequencing using a panel of genes commonly mutated in primary liver cancers. Alterat...

Hepatic fascioliasis as an important differential diagnosis to cholangiocarcinoma.
https://doi.org/10.1093/jtm/taab061
Journal of Travel Medicine; Serodio JF, Lopes M et. al.

Apr 14th, 2021 - Hepatic fascioliasis as an important differential diagnosis to cholangiocarcinoma.|2021|Serodio JF,Lopes M,Ribeiro R,Trindade M,Favas C,|

Spontaneous rupture of pyogenic liver abscess with subcapsular hemorrhage mimicking rup...
https://doi.org/10.1097/MD.0000000000025457
Medicine Kim NS, Chun HR et. al.

Apr 13th, 2021 - Spontaneous rupture of PLA (pyogenic liver abscess) is an extremely rare and life-threatening event. Ruptured PLA is very difficult to distinguish from malignant HCC (hepatocellular cancer) rupture or cholangiocarcinoma rupture on CT (computed tom...

GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042665
Oncology Reports; Zhou J, Nie W et. al.

Apr 13th, 2021 - Cholangiocarcinoma (CCA) is the second most common type of hepatocellular carcinoma characterized by high aggressiveness and extremely poor patient prognosis. The germ cell‑specific gene 2 protein (GSG2) is a histone H3 threonine‑3 kinase required...

Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: An individual...
https://doi.org/10.1016/j.amjsurg.2021.03.052
American Journal of Surgery; Ziogas IA, Esagian SM et. al.

Apr 12th, 2021 - We compared the outcomes of laparoscopic hepatectomy (LH) vs. open hepatectomy (OH) for intrahepatic cholangiocarcinoma (iCCA). A systematic review of the MEDLINE, EMBASE, Scopus, and Cochrane Library databases was performed using PRISMA guideline...

see more →

Guidelines  15 results

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 15th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.02178

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Hilar cholangiocarcinoma: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527854
HPB : the Official Journal of the International Hepato Pa... Mansour JC, Aloia TA et. al.

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Asia-Pacific consensus recommendations for endoscopic and interventional management of ...
https://doi.org/10.1111/jgh.12128
Journal of Gastroenterology and Hepatology; Rerknimitr R, Angsuwatcharakon P et. al.

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  9,435 results

Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Freque...
https://doi.org/10.1097/PAS.0000000000001716
The American Journal of Surgical Pathology; Tsai JH, Liau JY et. al.

Apr 16th, 2021 - The molecular characteristics of lymphoepithelioma-like intrahepatic cholangiocarcinoma (LELCC) remain elusive. We examined 27 LELCC cases through next-generation sequencing using a panel of genes commonly mutated in primary liver cancers. Alterat...

Hepatic fascioliasis as an important differential diagnosis to cholangiocarcinoma.
https://doi.org/10.1093/jtm/taab061
Journal of Travel Medicine; Serodio JF, Lopes M et. al.

Apr 14th, 2021 - Hepatic fascioliasis as an important differential diagnosis to cholangiocarcinoma.|2021|Serodio JF,Lopes M,Ribeiro R,Trindade M,Favas C,|

Spontaneous rupture of pyogenic liver abscess with subcapsular hemorrhage mimicking rup...
https://doi.org/10.1097/MD.0000000000025457
Medicine Kim NS, Chun HR et. al.

Apr 13th, 2021 - Spontaneous rupture of PLA (pyogenic liver abscess) is an extremely rare and life-threatening event. Ruptured PLA is very difficult to distinguish from malignant HCC (hepatocellular cancer) rupture or cholangiocarcinoma rupture on CT (computed tom...

GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferati...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042665
Oncology Reports; Zhou J, Nie W et. al.

Apr 13th, 2021 - Cholangiocarcinoma (CCA) is the second most common type of hepatocellular carcinoma characterized by high aggressiveness and extremely poor patient prognosis. The germ cell‑specific gene 2 protein (GSG2) is a histone H3 threonine‑3 kinase required...

Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: An individual...
https://doi.org/10.1016/j.amjsurg.2021.03.052
American Journal of Surgery; Ziogas IA, Esagian SM et. al.

Apr 12th, 2021 - We compared the outcomes of laparoscopic hepatectomy (LH) vs. open hepatectomy (OH) for intrahepatic cholangiocarcinoma (iCCA). A systematic review of the MEDLINE, EMBASE, Scopus, and Cochrane Library databases was performed using PRISMA guideline...

see more →

News  109 results

Europe Approves Pemigatinib for Bile Duct Cancer
https://www.medscape.com/viewarticle/948452

Mar 30th, 2021 - The European Commission has approved the oral targeted therapy pemigatinib (Pemazyre) for the treatment of locally advanced or metastatic cholangiocarcinoma, a rare cancer of the bile ducts. The indication is for patients with a fibroblast growth ...

Paving the Way for Diversity in Clinical Trials
https://www.medscape.com/viewarticle/947972

Mar 22nd, 2021 - "I'm the first person in my circle of family and friends to participate in a clinical trial." Five years ago, Rhonda Long was diagnosed with cholangiocarcinoma, a rare bile duct cancer that's seen in only about 8,000 Americans each year. At the ti...

Neoadjuvant Chemo for Intrahepatic Cholangiocarcinoma May Prolong Life
https://www.medscape.com/viewarticle/947254

Mar 11th, 2021 - NEW YORK (Reuters Health) - For patients with intrahepatic cholangiocarcinoma (ICC), the benefits of neoadjuvant chemotherapy (NAC) may extend beyond downstaging borderline resectable disease to improved overall survival, according to a small retr...

FDA Approves First Targeted Drug for Bile Duct Cancer
https://www.staging.medscape.com/viewarticle/928959

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

FDA Approves First Targeted Drug for Bile Duct Cancer
https://www.medscape.com/viewarticle/928959

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

see more →

Patient Education  23 results see all →